Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 9/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 9/20 | 0.53 |
| ▸ | CDK8 | P49336 | 2/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NEK2 | P51955 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26103034 | 0.84 | CYP11B2 (0.49) | CYP11B2CYP11B1CDK8NOTUMKDM4E | |
| SCHEMBL26103321 | 0.84 | CYP11B2 (0.49) | CYP11B2CYP11B1CDK8NOTUMKDM4E | |
| SCHEMBL5802241 | 0.84 | KDM4E (0.48) | NOTUMKDM4ECYP2C19NEK2CYP46A1 | |
| SCHEMBL6500699 | 0.81 | MAPT (0.55) | CYP11B2CYP11B1CDK8KDM4EMEN1 | |
| SCHEMBL5780030 | 0.78 | CYP11B2 (0.48) | CYP11B2CYP11B1CDK8CYP46A1 | |
| SCHEMBL1728859 | 0.78 | CYP11B2 (0.48) | CYP11B2CYP11B1CDK8 | |
| SCHEMBL239284 | 0.77 | CYP11B1 (0.52) | CYP11B2CYP11B1CDK8 | |
| SCHEMBL27856065 | 0.76 | CYP11B1 (0.61) | CYP11B2CYP11B1CDK8ALDH1A1LMNA | |
| SCHEMBL5820284 | 0.76 | KDM4E (0.48) | NOTUMKDM4ECYP2C19NEK2CYP46A1 | |
| SCHEMBL31342013 | 0.76 | CYP11B1 (0.72) | CYP11B2CYP11B1CDK8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| WO-2005019200-A2 | ARYL PIPERIDINE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019200-A2 | ARYL PIPERIDINE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | CYP11B2 2363/4885CYP11B1 2166/4885CDK8 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.